Seven Fleet Capital Management LP Takes Position in Celldex Therapeutics, Inc. $CLDX

Seven Fleet Capital Management LP acquired a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 29,300 shares of the biopharmaceutical company’s stock, valued at approximately $929,000.

Several other hedge funds have also modified their holdings of CLDX. Wilmington Savings Fund Society FSB acquired a new position in Celldex Therapeutics during the third quarter worth approximately $42,000. Russell Investments Group Ltd. raised its stake in Celldex Therapeutics by 27.6% during the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 501 shares during the period. Quantbot Technologies LP acquired a new position in shares of Celldex Therapeutics in the 3rd quarter valued at $63,000. Kestra Advisory Services LLC acquired a new position in shares of Celldex Therapeutics in the 4th quarter valued at $98,000. Finally, Advisory Services Network LLC purchased a new stake in shares of Celldex Therapeutics during the 3rd quarter valued at $139,000.

Celldex Therapeutics Stock Down 1.1%

CLDX opened at $38.06 on Friday. The firm has a market capitalization of $2.99 billion, a P/E ratio of -8.93 and a beta of 0.90. The firm’s 50 day moving average is $34.30 and its 200-day moving average is $31.03. Celldex Therapeutics, Inc. has a 52-week low of $19.72 and a 52-week high of $40.30.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.80 million. Equities analysts expect that Celldex Therapeutics, Inc. will post -4.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CLDX has been the subject of a number of research analyst reports. Wells Fargo & Company upped their price objective on Celldex Therapeutics from $48.00 to $72.00 and gave the stock an “overweight” rating in a report on Wednesday. Barclays lifted their target price on Celldex Therapeutics from $45.00 to $48.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Canaccord Genuity Group lowered their price target on Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Morgan Stanley dropped their price target on Celldex Therapeutics from $44.00 to $40.00 and set an “overweight” rating for the company in a research note on Wednesday, July 22nd. Finally, Cantor Fitzgerald cut their price objective on Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating on the stock in a report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $54.62.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.